Trial Profile

A phase II/III trial of PRV-002 to treat Traumatic-brain-injuries (concussion)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 21 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jul 2025 According to an Oragenics Inc media release, the company has entered into a purchase and sale agreement of up to 800,000 shares of its Series H Convertible Preferred Stock and Warrants to purchase up to an additional 800,000 shares of its Preferred Stock. The gross proceeds of these transactions will be approximately $20.00 million. The Company intends to use these proceeds, along with existing cash, to fund its ongoing ONP-2 clinical trials.
08 Aug 2024 According to a Oragenics Inc media release, the company has completed FDA-Required cardiotoxicity testing, prior to conducting trial in USA.
19 Dec 2022 According to an Odyssey Pharmaceuticals Inc media release, the company is seeking sites in Australia to start the Phase II trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com